DK1553950T3 - Terapeutisk behandling - Google Patents

Terapeutisk behandling

Info

Publication number
DK1553950T3
DK1553950T3 DK03751038T DK03751038T DK1553950T3 DK 1553950 T3 DK1553950 T3 DK 1553950T3 DK 03751038 T DK03751038 T DK 03751038T DK 03751038 T DK03751038 T DK 03751038T DK 1553950 T3 DK1553950 T3 DK 1553950T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
DK03751038T
Other languages
English (en)
Inventor
Francis Thomas Boyle
Jon Owen Curwen
Neil James Gallagher
Ursula Joy Hancox
Andrew Mark Hughes
Donna Johnstone
Sian Tomiko Taylor
David William Tonge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1553950T3 publication Critical patent/DK1553950T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03751038T 2002-10-12 2003-10-07 Terapeutisk behandling DK1553950T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (1)

Publication Number Publication Date
DK1553950T3 true DK1553950T3 (da) 2007-10-15

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03751038T DK1553950T3 (da) 2002-10-12 2003-10-07 Terapeutisk behandling

Country Status (30)

Country Link
US (1) US20060122180A1 (da)
EP (1) EP1553950B1 (da)
JP (1) JP2006510605A (da)
KR (1) KR20050056238A (da)
CN (1) CN100342853C (da)
AR (1) AR041595A1 (da)
AT (1) ATE369136T1 (da)
AU (1) AU2003269259B2 (da)
BR (1) BR0315140A (da)
CA (1) CA2501959A1 (da)
CY (1) CY1107605T1 (da)
DE (1) DE60315490T2 (da)
DK (1) DK1553950T3 (da)
ES (1) ES2289316T3 (da)
GB (1) GB0223854D0 (da)
HK (1) HK1078784A1 (da)
IS (1) IS2473B (da)
MX (1) MXPA05003808A (da)
MY (1) MY135441A (da)
NO (1) NO20051658L (da)
NZ (1) NZ539137A (da)
PL (1) PL375584A1 (da)
PT (1) PT1553950E (da)
RU (1) RU2005114487A (da)
SA (1) SA04240502B1 (da)
TW (1) TW200412971A (da)
UA (1) UA82492C2 (da)
UY (1) UY28017A1 (da)
WO (1) WO2004035057A1 (da)
ZA (1) ZA200502874B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
MX2010003989A (es) * 2007-10-12 2010-04-27 Astrazeneca Ab Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
DK2464218T3 (da) * 2009-08-10 2015-07-20 Univ Texas Behandling af hjernemetastaser med inhibitorer af endothelin-receptorer i kombination med et cytotoksisk middel til kemoterapi
US20220265628A1 (en) * 2019-07-17 2022-08-25 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
TW202317555A (zh) 2021-06-22 2023-05-01 日商亞克醫藥股份有限公司 化合物、內皮素a受體拮抗劑及醫藥組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
OA11769A (en) * 1998-04-29 2005-07-25 Pfizer Prod Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate.
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
EP1553950A1 (en) 2005-07-20
ATE369136T1 (de) 2007-08-15
NO20051658L (no) 2005-05-06
CA2501959A1 (en) 2004-04-29
CN1703224A (zh) 2005-11-30
WO2004035057A1 (en) 2004-04-29
AU2003269259A1 (en) 2004-05-04
GB0223854D0 (en) 2002-11-20
RU2005114487A (ru) 2006-02-10
IS7825A (is) 2005-04-26
NZ539137A (en) 2008-01-31
AR041595A1 (es) 2005-05-26
PL375584A1 (en) 2005-11-28
US20060122180A1 (en) 2006-06-08
CN100342853C (zh) 2007-10-17
DE60315490D1 (de) 2007-09-20
SA04240502B1 (ar) 2008-09-14
CY1107605T1 (el) 2013-03-13
PT1553950E (pt) 2007-09-26
KR20050056238A (ko) 2005-06-14
ZA200502874B (en) 2006-02-22
MY135441A (en) 2008-04-30
UA82492C2 (uk) 2008-04-25
IS2473B (is) 2008-12-15
HK1078784A1 (en) 2006-03-24
MXPA05003808A (es) 2005-06-08
AU2003269259B2 (en) 2007-03-15
TW200412971A (en) 2004-08-01
DE60315490T2 (de) 2008-05-08
JP2006510605A (ja) 2006-03-30
BR0315140A (pt) 2005-08-16
ES2289316T3 (es) 2008-02-01
EP1553950B1 (en) 2007-08-08
UY28017A1 (es) 2004-04-30

Similar Documents

Publication Publication Date Title
NO20052914D0 (no) Terapeutiske forbindelser
DE60328797D1 (de) Blutbehandlungsgerät
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
GB0316912D0 (en) Therapeutic treatment
DE60311298D1 (de) Kopfhautbehandlung
GB0320806D0 (en) Therapeutic treatment
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20050689L (no) Terapeutisk anvendelse
GB0223367D0 (en) Therapeutic treatment
ATE389742T1 (de) Gewebebehandlungsmittel
DK1597171T3 (da) Terapeutisk mikroskum
ATA13602003A (de) Therapeutisches behandlungsgerät
DE60326734D1 (de) Ligations-behandlungsgerät
GB0210464D0 (en) Therapeutic treatment
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
NO20022747D0 (no) Behandlingsstol
NO20042850L (no) Kreftbehandling
SE0200450D0 (sv) Therapeutic agents
SE0203826D0 (sv) Therapeutic agents
FI20020356A0 (fi) Sauna
ITPG20020067A1 (it) Dermo terapia
SE0203451D0 (sv) Therapeutic Heterocycles